Short answer
Aardvark Therapeutics, Inc. (AARD) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$14M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$14M
- −0.1% YoY · +33.4% QoQ
- EPS (diluted)
- −$0.66
- −1.5% YoY · +33.3% QoQ
Source: XBRL data from the Aardvark Therapeutics, Inc. (AARD) Q2 2026 10-Q on SEC EDGAR. USD.
Aardvark Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered clinical risk: reversible cardiac observations paused HERO, OLE, POWER, and STRENGTH trials in February 2026
- Most materially updated development risk: FDA full clinical hold on ARD-101 IND in May 2026, followed by HERO and OLE termination in June 2026
- Regulatory risk: future ARD-101 development depends on FDA discussions after program-wide data unblinding and safety-strategy updates
- Operational risk: ARD-101 dependence intensified as terminated PWS trials will not resume as previously designed
- Financial risk: $73.9 million cash, cash equivalents, and short-term investments fund projected operations into late 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aardvark Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.